These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28453615)

  • 1. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
    Aggarwal A; Fojo T; Chamberlain C; Davis C; Sullivan R
    Ann Oncol; 2017 Aug; 28(8):1738-1750. PubMed ID: 28453615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
    Leigh S; Granby P
    Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.
    Chamberlain C; Collin SM; Stephens P; Donovan J; Bahl A; Hollingworth W
    Br J Cancer; 2014 Oct; 111(9):1693-702. PubMed ID: 24569469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cancer Drugs Fund in Practice and Under the New Framework.
    Sabry-Grant C; Malottki K; Diamantopoulos A
    Pharmacoeconomics; 2019 Jul; 37(7):953-962. PubMed ID: 30941698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
    Linley WG; Hughes DA
    Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review.
    Dixon P; Chamberlain C; Hollingworth W
    Value Health; 2016; 19(6):879-884. PubMed ID: 27712717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "What's fair to an individual is not always fair to a population": A qualitative study of patients and their health professionals using the Cancer Drugs Fund.
    Chamberlain C; Owen-Smith A; MacKichan F; Donovan JL; Hollingworth W
    Health Policy; 2019 Aug; 123(8):706-712. PubMed ID: 31279588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
    Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
    Front Public Health; 2022; 10():964040. PubMed ID: 36187695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.